MINOCA分层治疗随机试验PROMISE
PROMISE是首个评估MINOCA治疗策略的随机试验,将101例患者随机分配至基于全面诊断病因的分层治疗或标准治疗。92例确认MINOCA并纳入分析,12个月时分层治疗组西雅图心绞痛问卷汇总评分显著优于标准治疗组,组间平均差+9.38(95%CI 6.81–11.95;P<.001)。MACE在分层治疗组1例(2.2%)、标准治疗组4例(8.5%),差异无统计学意义(P=.18)。
要点
- 分层治疗基于全面诊断评估和病因导向治疗。
- 12个月心绞痛相关健康状况显著改善,组间平均差+9.38。
- MACE差异无统计学意义,需更大样本验证。
核心结论
- 基于全面诊断评估和病因导向治疗的分层治疗显著改善MINOCA患者12个月心绞痛相关健康状况。
- 研究结果为这一异质性且常被低估人群的个体化管理提供了首个证据,但需更大样本和更长随访确认。
研究设计与样本
- 多中心随机试验,将MINOCA患者1:1随机分配至分层治疗或标准治疗。
- 共101例随机,92例确认MINOCA纳入最终分析(平均年龄62±13岁,48%女性;分层治疗n=45;标准治疗n=47)。
- 主要终点为12个月时西雅图心绞痛问卷汇总评分(SAQSS)变化值的组间差异。
- 次要终点为主要不良心血管事件(MACE),定义为全因死亡、心肌梗死、卒中、心力衰竭住院和重复冠状动脉造影的复合终点。
- 因干预组明显获益和对照组潜在 harm,试验经数据与安全监察委员会建议提前终止。
主要发现
- 12个月随访时,分层治疗组SAQSS显著高于标准治疗组,组间平均差+9.38(95%CI 6.81–11.95;P<.001)。
- MACE在分层治疗组发生1例(2.2%),标准治疗组发生4例(8.5%),差异无统计学意义(P=.18)。
临床怎么用
- 对MINOCA患者可考虑基于全面诊断评估明确病因后给予分层治疗,以改善心绞痛相关健康状况。
- MACE获益尚不明确,需更大样本和更长随访验证。
局限性
- 样本量小(最终分析92例),MACE差异无统计学意义。
- 试验因干预组明显获益和对照组潜在 harm 提前终止。
- 结果需更大样本和更长随访确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND AIMS: Myocardial infarction with non-obstructive coronary arteries (MINOCA) is associated with a significant risk of mortality, rehospitalization, and angina burden. Despite its clinical impact, no randomized clinical trials have hitherto evaluated optimal management strategy for MINOCA. The PROMISE trial was designed to assess whether a stratified treatment improves clinical outcomes in patients with MINOCA as compared to standard care. METHODS: PROMISE is a multicentre randomized trial. Patients with MINOCA were randomized 1:1 to either a stratified treatment based on a comprehensive diagnostic workup aimed at identifying the underlying aetiology, or to standard care. The primary endpoint was the between-group difference in the change in angina status at 12 months, assessed by the Seattle Angina Questionnaire summary score (SAQSS). The secondary endpoint was the incidence of major adverse cardiovascular events (MACE), defined as the composite of all-cause mortality, myocardial infarction, stroke, heart failure hospitalization and repeated coronary angiography. The trial was terminated early upon recommendation by the Data and Safety Monitoring Board due to clear benefits observed in the intervention group and potential harm in the control group. RESULTS: Of 101 randomized patients, 92 were confirmed as MINOCA and included in the final analysis (mean age 62 ± 13 years, 48% women; stratified treatment n = 45; standard care n = 47). At 12-month follow-up, SAQSS was significantly higher in the stratified treatment than in standard care group, with a mean between-group difference of +9.38 in favour of the stratified treatment (95% confidence interval 6.81 to 11.95; P < .001). MACE occurred in 1 patient (2.2%) in the stratified treatment and in 4 patients (8.5%) in the standard care group, though the difference was not statistically significant (P = .18). CONCLUSIONS: In this first randomized trial of treatment strategies in MINOCA, a stratified treatment, based on comprehensive diagnostic assessment and aetiology-guided therapy, led to a significant improvement in angina-related health status. While the study findings provide the first evidence supporting individualized management in this heterogeneous and often under-recognized patient population, these results require confirmation in a larger prospective study with longer follow-up.
引用
- Montone, Cosentino, Gorla, et al. Stratified treatment of myocardial infarction with non-obstructive coronary arteries: the PROMISE trial. Eur Heart J. 2026. PMID: 41150941. doi:10.1093/eurheartj/ehaf917
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。